home > news > detailed info

Novo Nordisk to Acquire Emisphere Technologies for $1.35 Billion

Emisphere Technologies

ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk A/S (“Novo Nordisk”), whereby Novo Nordisk will acquire Emisphere, on a cash-free, debt-free basis, for $1.35 billion in cash. The consideration to be paid per share will depend on the amount of cash and debt at closing, but the Company currently estimates it to be approximately $7.82 per share based on approximately 170.9 million fully diluted shares outstanding. This price represents a premium of approximately 17% over the volume-weighted average Emisphere share price for the five trading days ending on November 5, 2020.

Novo Nordisk and Emisphere have collaborated since 2007, on Emisphere’s proprietary drug delivery technology Eligen®, which facilitates the enhanced oral absorption of molecules without altering their chemical form, biological integrity or pharmacological properties. Novo Nordisk is currently utilizing Emisphere’s carrier technology under an existing license agreement in its oral formulation of a GLP-1 receptor agonist semaglutide, which is marketed and sold under the brand name Rybelsus®.

Contemporaneously with this agreement, Novo Nordisk entered into an agreement to acquire the related royalty stream obligations owed to affiliates of MHR Fund Management LLC (“MHR”) for $450 million. The acquisition of this royalty stream and the merger with Emisphere will occur simultaneously.

The Board of Directors of Emisphere approved the merger, upon the unanimous recommendation of a Special Committee consisting entirely of independent and disinterested Emisphere directors. MHR and the directors of Emisphere (collectively owning a majority of the outstanding Emisphere shares) have agreed to vote their shares in favor of the transaction.

“After a thorough analysis of strategic alternatives, the Emisphere Board and the Special Committee unanimously determined that a combination with Novo Nordisk is the best way to maximize value for our stockholders,” said Timothy G. Rothwell, Chairman of Emisphere.

“MHR was an early believer in Emisphere and its proprietary Eligen drug delivery technology. Our longstanding support of the company was validated when its partnership with Novo Nordisk resulted in the development of an oral formulation for GLP-1, which we believe will be a transformative drug for the treatment of Type 2 diabetes. We are immensely proud of the pivotal role we have played in Emisphere’s success, culminating in today’s announced transaction with Novo Nordisk, which will deliver immediate and substantial value to all Emisphere shareholders,” said Mark H. Rachesky, M.D., Founder of MHR and a member of the board of Emisphere.

The merger is subject to customary closing conditions, including approval by Emisphere stockholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Emisphere is represented by Wachtell, Lipton, Rosen & Katz as legal advisor. Jefferies LLC is acting as the Emisphere Special Committee’s financial advisor and Wilmer Cutler Pickering Hale and Dorr LLP is acting as its legal advisor.

About Eligen® Carrier Technology

Eligen® technology enables drug therapies to be provided in a tablet formulation with an absorption-enhancing excipient. Emisphere created Eligen® technology, its proprietary oral drug delivery platform, to facilitate the absorption of small and large molecules without altering their chemical form, biological integrity or pharmacological properties. Notably, the technology enables the transport of therapeutic molecules including large peptides and proteins across biological membranes such as those of the gastrointestinal tract.

About Emisphere Technologies

Emisphere is a drug delivery company that utilises its proprietary technologies to develop new oral formulations of therapeutic agents. For more information, please visit the Company's website at


Emisphere Technologies, Inc.

Michelle Pappanastos
Argot Partners
phone 973 532 8000
email 4 Becker Farm Road Suite 103 Roseland NJ 07068
Print this page
Send to a friend
News and Press Releases

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

Acquisition will add another key dimension to Boehringer Ingelheim’s focus on patients with difficult-to-treat solid tumors NBE-Therapeutics’ pipeline is based on its innovative next generation antibody-drug conjugate (ADC) technology platform NBE-Therapeutics’ will remain at its campus in Basel, Switzerland and operate as a new site within Boehringer Ingelheim’s R&D network
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement